Autoimmune Uveitis Market Expected to rise, 2034 | Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., expected to drive market

The Autoimmune Uveitis market growth is driven by factors like increase in the prevalence of Autoimmune Uveitis, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Autoimmune Uveitis market report [https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Autoimmune Uveitis market size, share, Autoimmune Uveitis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Autoimmune Uveitis market size growth forward.

Some of the key highlights from the Autoimmune Uveitis Market Insights Report:

*
Several key pharmaceutical companies, including Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others, are developing novel products to improve the Autoimmune Uveitis treatment outlook.

*
In 2022, the Autoimmune Uveitis market size across the seven major markets (7MM) was approximately USD 1,290 million and is projected to grow significantly by 2034 at a notable compound annual growth rate (CAGR).

*
The United States accounted for the largest share, with a market size of around USD 840 million in 2022, while Italy had the smallest share, at USD 39 million, both of which are expected to increase by 2034. The highest number of autoimmune uveitis patients was observed in the US, followed by the EU4 countries, the UK, and Japan.

*
The distribution of autoimmune uveitis subtypes-such as anterior noninfectious uveitis (aNIU), pan-uveitis, and posterior uveitis-plays a critical role in determining treatment strategies, prognosis, and healthcare resource allocation. Diagnosed cases of aNIU were the most prevalent throughout the study period in the 7MM.

*
HUMIRA remains the only FDA-approved biologic treatment for autoimmune uveitis. In 2022, biologics dominated the market, contributing approximately USD 960 million of the total market size. The autoimmune uveitis treatment market is expected to witness substantial growth in the coming years.

*
The autoimmune uveitis treatment market is expected to grow during the forecast period, driven by the introduction of emerging therapies such as TRS01, OCS-02, and EYS606.

Strategise your business goals by understanding market dynamics @ Autoimmune Uveitis Market Landscape [https://www.delveinsight.com/sample-request/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Autoimmune Uveitis Overview

Autoimmune uveitis is an inflammatory condition affecting the uveal components of the eye, caused by autoimmune reactions to self-antigens or external triggers. It may occur as an isolated condition or alongside systemic autoimmune or auto-inflammatory diseases. While primarily impacting the uvea, it can also affect other eye structures. Autoimmune uveitis is classified as infectious or noninfectious, with the latter often linked to systemic autoimmune conditions. Symptoms include blurred vision, eye pain, photophobia, redness, and floaters, though children can be asymptomatic. Managing noninfectious uveitis (NIU) requires early and accurate diagnosis for timely treatment.

Diagnosis starts with a review of symptoms and a detailed examination of both the anterior and posterior eye segments. A systemic workup includes lab tests, chest X-rays, and advanced diagnostic tools like optical coherence tomography (OCT) and fluorescein angiography. Tests such as slit lamp examination, funduscopic exam, visual acuity, and ocular pressure evaluation confirm the condition. In ambiguous cases, serologic testing for syphilis and chest radiography for sarcoidosis or tuberculosis are recommended.

The diagnostic journey typically begins when patients experience risk factors such as infections, genetic predispositions, or post-surgical complications. They are referred by general physicians to ophthalmologists, who conduct specific diagnostic tests. However, there is no standardized diagnostic approach for uveitis, emphasizing the need for individualized evaluation and care.

Do you know the treatment paradigms for different countries? Download our Autoimmune Uveitis Market Sample Report [https://www.delveinsight.com/sample-request/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Autoimmune Uveitis Epidemiology Insights

*
In 2022, there were approximately 0.9 million diagnosed prevalent cases of uveitis and 0.6 million cases specifically of autoimmune uveitis across the 7MM, with these numbers expected to rise by 2034 due to an aging population. Uveitis can be classified as either infectious or noninfectious. According to epidemiological data, 0.1 million cases were infectious, while 0.7 million were noninfectious in 2022.

*
Noninfectious uveitis (NIU) was further categorized by anatomical location: anterior noninfectious uveitis (aNIU), posterior uveitis, intermediate uveitis, and pan-uveitis. Among these, aNIU accounted for the highest number of cases, with 0.5 million in 2022. This prevalence may be attributed to variations in autoimmune mechanisms, environmental factors, and the comparatively straightforward diagnosis of aNIU.

*
The United States had the largest share of diagnosed prevalent cases of autoimmune uveitis in 2022, with 0.29 million cases, a figure expected to grow by 2034. In Europe (EU4 and the UK), there were 0.26 million diagnosed cases, with Germany contributing the most at 73,000 cases. Meanwhile, Japan accounted for 17% of the total diagnosed prevalent cases in the 7MM, amounting to 0.1 million cases in 2022.

Autoimmune Uveitis Epidemiology Segmentation

DelveInsight's Autoimmune Uveitis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Autoimmune Uveitis historical patient pools and forecasted Autoimmune Uveitis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Autoimmune Uveitis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Autoimmune Uveitis Prevalence

*
Age-Specific Autoimmune Uveitis Prevalence

*
Gender-Specific Autoimmune Uveitis Prevalence

*
Diagnosed and Treatable Cases of Autoimmune Uveitis

Visit for more @ Autoimmune Uveitis Epidemiological Insights [https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Autoimmune Uveitis Market Insights:

*
Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Autoimmune Uveitis (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.

*
According to DelveInsight's patient-based forecasting model, the total aHUS market size in the 7MM was approximately USD 1,300 million in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.

*
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.

*
Among emerging therapies for aHUS, Novartis' iptacopan and Roche's crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Autoimmune Uveitis Market Outlook

Managing noninfectious uveitis (NIU) and other autoimmune conditions is rarely straightforward, as it typically involves more than targeting a single molecule or mechanism. However, the approval of biologic treatments, such as HUMIRA, has marked significant progress, including specific options for NIU.

Local therapies for NIU primarily rely on corticosteroids, although intraocular injections of agents like sirolimus and methotrexate have also been explored. Current approved treatments include topical steroids, shorter-acting intraocular and periocular steroids such as triamcinolone acetonide, and sustained-release intravitreal implants like OZURDEX and YUTIQ.

The anticipated introduction of new therapies for autoimmune uveitis, including TRS01 eye drops (for noninfectious anterior uveitis), OCS-02 (for acute anterior uveitis), and EYS606: a combination product (for chronic noninfectious uveitis), is expected to significantly enhance the treatment landscape and positively influence the market.

Autoimmune Uveitis Marketed Drugs

*
YUTIQ: Eyepoint Pharmaceuticals

*
HUMIRA (Adalimumab): AbbVie Inc.

Autoimmune Uveitis Emerging Drugs

*
TRS01: Tarsier Pharma

*
OCS-02: Oculis Pharma

Autoimmune Uveitis Key Companies

*
Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others

For more information, visit Autoimmune Uveitis Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Autoimmune Uveitis Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Autoimmune Uveitis, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Autoimmune Uveitis epidemiology in the 7MM

*
Autoimmune Uveitis marketed and emerging therapies

*
Autoimmune Uveitis companies

*
Autoimmune Uveitis market drivers and barriers

Table of Contents:

1 Autoimmune Uveitis Market Key Comprehensive Insights

2 Autoimmune Uveitis Market Report Introduction

3 Competitive Intelligence Analysis for Autoimmune Uveitis

4 Autoimmune Uveitis Market Analysis Overview at a Glance

5 Executive Summary of Autoimmune Uveitis

6 Autoimmune Uveitis Epidemiology and Market Methodology

7 Autoimmune Uveitis Epidemiology and Patient Population

8 Autoimmune Uveitis Patient Journey

9 Autoimmune Uveitis Treatment Algorithm, Autoimmune Uveitis Current Treatment, and Medical Practices

10 Key Endpoints in Autoimmune Uveitis Clinical Trials

11 Autoimmune Uveitis Marketed Therapies

12 Autoimmune Uveitis Emerging Therapies

13 Autoimmune Uveitis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Autoimmune Uveitis

16 Autoimmune Uveitis Market Key Opinion Leaders Reviews

18 Autoimmune Uveitis Market Drivers

19 Autoimmune Uveitis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Autoimmune Uveitis Epidemiology 2034

DelveInsight's "Autoimmune Uveitis - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Autoimmune Uveitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Autoimmune Uveitis Pipeline 2024

"Autoimmune Uveitis Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Autoimmune Uveitis market. A detailed picture of the Autoimmune Uveitis pipeline landscape is provided, which includes the disease overview and Autoimmune Uveitis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=autoimmune-uveitis-market-expected-to-rise-2034-tarsier-pharma-eli-lilly-and-company-oculis-pharma-eyevensys-priovant-therapeutics-inc-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.